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2% (54 cases) of the cases with a diagnosis of normal, tonsillitis, or hyperplasia were randomly reviewed to determine the percentage of potentially misdiagnosed routine cases.
Study design
This was a retrospective cohort study, carried out in hospitals and clinics affiliated to a university. The duration of the follow-up appears to be different for each study patient, and based on the presentation provided in the paper, ranged from zero to six years. Loss to follow-up was not reported. The diagnosis from the pathology report was compared with the diagnosis on retrospective histologic review, and the number of discrepancies was recorded. One of the authors who was unaware of the original diagnosis and history reviewed the slides.
Analysis of effectiveness
The principle used in the analysis of effectiveness was not explicitly specified. The main clinical outcome was a potential, or actual, effect on patient care as a result of pathologic examination. The following conditions for the existence of a potential effect on patient care were considered:
(1) the pathologic diagnosis was not normal, tonsillitis, or hyperplasia;
(2) the clinical history was significant (a reported clinical diagnosis other than normal, tonsillitis, or hyperplasia); and (3) the pathologic diagnosis was consequential (for example, granulomatous disease, which could affect patient care).
The discordant rate was also reported.
Effectiveness results
The number of cases with a diagnosis other than normal, tonsillitis, or hyperplasia were: routine, 27 (1%); and non routine, 56 (79%). 12 out of 67 routine cases did not have a significant clinical history; only 6 cases had a potentially significant pathologic diagnosis. Chart review of these 6 patients showed that in none of them did the pathologic diagnosis affect the actual patient care. In all non-routine cases, the pathologic diagnosis affected patient care. In routine cases, the concordance rate was 100% based on the comparison between the retrospective histologic review of the 27 cases and the original histologic diagnoses. In 54 randomly selected cases, with a pathologic diagnosis of normal, tonsillitis, or hyperplasia, the corresponding rate was also 100%. In non-routine specimens, the overall concordance rate between the clinical and pathologic diagnoses was 89%. A concordance rate of 100% was achieved when the retrospective histologic diagnoses were compared with the original histologic diagnoses.
Clinical conclusions
For routine T&A specimens, the incidence of clinically significant disease was remarkably low. In only 1% (27 out of 2700) of cases from a period somewhat longer than 10 years was the pathologic diagnosis something other than benign, tonsillitis, or hyperplasia. Pathologic diagnoses did not affect actual patient care in any cases. For non-routine specimens, the incidence of malignancy was 39%. However, even in cases in which the pathologic diagnosis was not cancer, the pathologic diagnosis still affected patient care.
Measure of benefits used in the economic analysis
A potential or an actual effect on patient care as a result of pathologic examination (unexpected diagnosis).
Direct costs
Costs were not discounted due to the short time frame of the cost analysis. Quantities were reported separately from the costs only in terms of the average number of blocks submitted per case and the number of ancillary studies performed. Cost items were reported separately. The cost analysis covered the costs of technical and professional services, and ancillary studies such as immunoperoxidase, direct immunofluorescence, gene rearrangement, and other special stain
Validity of estimate of costs
Some quantities were reported separately from the costs. Adequate details of the methods of cost estimation were given. Using charge data instead of true costs may have adversely affected the external validity of the cost analysis. The authors used charges only to provide a reference by which to compare test utility. The price date was given. The perspective adopted in the cost analysis was not explicitly specified. No statistical analysis was performed on either the resource use data or the cost data. The possible impact of the alternative health technologies on indirect costs (productivity loss or gain) was not discussed.
Other issues
In view of the retrospective nature of the study design, lack of sensitivity analysis and statistical analysis of resources used and costs, the study results may need to be interpreted with some degree of caution. The issue of generalisability to other settings or countries was not addressed. Appropriate comparisons were made with other studies. The study covered only the T&A specimens (as an example) and this appears to be reflected in the generalisations made in the authors' comments. The authors stated that they performed a cost-benefit analysis, but, as health outcomes were not measured in monetary terms, the study could be more correctly regarded as a cost-effectiveness study.
Implications of the study
When routine T&A specimens are removed because of repeated infection or enlargement, a gross-only examination or no examination should be performed. Any atypical clinical history, such as the possibility of a lymphoproliferative disease should result in a histologic examination even of routine specimens. A careful clinical examination of the patient is equally important. The data also indicate that there is no specific age cut-off beyond which histologic examination should always be performed.
Source of funding
None stated.
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